Cargando…

Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma

Chimeric antigen receptor (CAR) T-cell immunotherapy following autologous stem cell transplantation (ASCT) is a promising method for refractory or relapsed multiple myeloma, but explicit data for central nervous system lymphoma (CNSL) are lacking. Here, we treated 13 CNSL patients with ASCT sequenti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Jiaying, Meng, Fankai, Cao, Yang, Zhang, Yicheng, Zhu, Xiaojian, Wang, Na, Wang, Jue, Huang, Lifang, Zhou, Jianfeng, Xiao, Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282870/ https://www.ncbi.nlm.nih.gov/pubmed/34267187 http://dx.doi.org/10.1038/s41408-021-00523-2

Ejemplares similares

Sequential CAR T-Cell Therapy After Autologous Stem Cell Transplantation for the Treatment of Relapsed/Refractory Intravascular Large B-Cell Lymphoma With Central Nervous System Involvement: A Case Report
por: Liu, Wanying, et al.
Publicado: (2022)

Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma
por: Wei, Jia, et al.
Publicado: (2019)

Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma
por: Wu, Jiaying, et al.
Publicado: (2022)

CAR T-Cell Therapy Is Effective but Not Long-Lasting in B-Cell Lymphoma of the Brain
por: Li, Tongjuan, et al.
Publicado: (2020)

Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30(+) lymphoma
por: Zhang, Peiling, et al.
Publicado: (2022)

Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT
por: Wei, Jia, et al.
Publicado: (2022)

Case report: Sandwich therapy of CAR-T combined with ASCT: Sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed/refractory Burkitt’s lymphoma with TP53 mutations
por: Zhang, Qi, et al.
Publicado: (2023)

Immunotherapy of B cell lymphoma with CD22-redirected CAR NK-92 cells
por: Tian, Xiaopeng, et al.
Publicado: (2023)

Long‐term outcomes of relapsed/refractory double‐hit lymphoma (r/r DHL) treated with CD19/22 CAR T‐cell cocktail therapy
por: Wei, Jia, et al.
Publicado: (2020)

A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy
por: Li, Tongjuan, et al.
Publicado: (2019)

T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell Lymphoma
por: Wang, Jiachen, et al.
Publicado: (2022)

Demethylating therapy increases cytotoxicity of CD44v6 CAR-T cells against acute myeloid leukemia
por: Tang, Ling, et al.
Publicado: (2023)

Sequential CAR T cell and targeted alpha immunotherapy in disseminated multiple myeloma
por: Awuah, Dennis, et al.
Publicado: (2023)

MYC/BCL2/BCL6 triple hit and TP53 deletion in a case of high-grade B cell lymphoma receiving CAR T cell immunotherapy
por: Wang, Jiachen, et al.
Publicado: (2021)

CAR T-cell therapy for mantle cell lymphoma with central nervous system relapse
por: Vu, Khoan, et al.
Publicado: (2022)

Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma
por: Jackson, Zachary, et al.
Publicado: (2020)

Upregulation of CD22 by Chidamide promotes CAR T cells functionality
por: Yang, Xin, et al.
Publicado: (2021)

Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL
por: Meng, Yuan, et al.
Publicado: (2021)

Lymphoma immunotherapy: Efficacy, safety and accessibility to CAR-T therapy for lymphomas
por: Borchmann, Peter
Publicado: (2018)

Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells
por: Koristka, Stefanie, et al.
Publicado: (2019)

Corrigendum: Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL
por: Meng, Yuan, et al.
Publicado: (2021)

Sequential different B-cell antigen–targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphoma
por: Liu, Ying, et al.
Publicado: (2022)

The Role of Autologous Stem Cell Transplantation in the Treatment of Diffuse Large B-cell Lymphoma in the Era of CAR-T Cell Therapy
por: Lekakis, Lazaros J., et al.
Publicado: (2019)

CAR T-cell therapy for central nervous system lymphomas: blood and cerebrospinal fluid biology, and outcomes
por: Lacan, Claire, et al.
Publicado: (2023)

CAR T-Cell Immunotherapy Treating T-ALL: Challenges and Opportunities
por: Ren, Anqi, et al.
Publicado: (2023)

T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy
por: Mehta, Palak H., et al.
Publicado: (2021)

Autologous stem cell transplantation for large B-cell lymphoma with secondary central nervous system involvement
por: Akin, Serkan, et al.
Publicado: (2022)

Generating universal chimeric antigen receptor expressing cell products from induced pluripotent stem cells: beyond the autologous CAR-T cells
por: Deng, Xinyue, et al.
Publicado: (2023)

From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies
por: Lu, Hui, et al.
Publicado: (2021)

Versatile CAR T-cells for cancer immunotherapy
por: Chu, Fuliang, et al.
Publicado: (2018)

Tuning the performance of CAR T cell immunotherapies
por: Richardson, Noah H., et al.
Publicado: (2019)

Adoptive Immunotherapy beyond CAR T-Cells
por: Titov, Aleksei, et al.
Publicado: (2021)

Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma
por: Xu, Jinhuan, et al.
Publicado: (2018)

CD19 and CD30 CAR T-Cell Immunotherapy for High-Risk Classical Hodgkin’s Lymphoma
por: Xue, YuanBo, et al.
Publicado: (2021)

Outcome of Patients with Diffuse Large B-Cell Lymphoma Relapsing after Autologous Transplant before Availability of CAR-T Cell Treatment
por: von Matt, Stefanie, et al.
Publicado: (2023)

Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion
por: Gumber, Diana, et al.
Publicado: (2022)

Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphoma
por: Zhang, Huanxin, et al.
Publicado: (2022)

CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma
por: Mohty, Razan, et al.
Publicado: (2022)

Engineering light-controllable CAR T cells for cancer immunotherapy
por: Huang, Ziliang, et al.
Publicado: (2020)

Primary Autologous Stem Cell Transplantation for Unilateral Primary Central Nervous System Lymphoma–Ophthalmic Variant (Primary Vitreoretinal Lymphoma)
por: Lee, Brian, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_scpmm1se0ftvd5edsp9a1uphm0